MiNA Therapeutics is the global leader in small activating RNA therapeutics or RNAa. Harnessing innate mechanisms of gene activation, RNAa therapeutics are a revolutionary new class of medicines that can restore or boost normal function of genes and thereby protein-modulated pathways in cells.
We are advancing a proprietary pipeline of new medicines with an initial focus on genetic medicine, while collaborating with leading pharmaceutical companies to apply our technology platform across a broad range of other therapeutic areas.
PIONEERING NEW CLASS OF MEDICINES
RNAa therapeutics are an entirely new class of medicines with potential to offer transformational and curative treatment options to patients across a wide range of diseases.
Our first RNAa medicine has been evaluated in clinical trials in over 120 patients and has achieved clinical Proof of Concept.
Our team have developed a systematic approach to take new RNAa medicines from an idea to patients in a clinical trial in just 2 years.